Joelf Posted October 29, 2019 Share Posted October 29, 2019 Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Exogenous replacement of IL-36 antagonists may be a novel promising therapeutic target for PsA patients. PubMed, Rheumatology (Oxford), 09/03/2019. (Also see Psoriasis and Psoriatic Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles. Quote Link to post Share on other sites
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.